Regeneron Pharmaceuticals’ (REGN) Outperform Rating Reiterated at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “outperform” rating restated by equities research analysts at BMO Capital Markets in a research report issued on Tuesday, Benzinga reports. They currently have a $1,300.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price target suggests a potential upside of 23.88% from the stock’s previous close.

Several other equities analysts have also recently weighed in on REGN. Wells Fargo & Company reaffirmed an “overweight” rating and set a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,120.05.

Regeneron Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ REGN traded down $42.54 during mid-day trading on Tuesday, reaching $1,049.44. The company had a trading volume of 387,198 shares, compared to its average volume of 472,493. The stock’s 50 day moving average is $1,131.94 and its 200-day moving average is $1,033.46. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock has a market capitalization of $115.63 billion, a PE ratio of 30.82, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the company earned $8.79 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold 9,270 shares of company stock worth $10,695,833 in the last 90 days. Insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. West Paces Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.